{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:04Z","timestamp":1790797084170,"version":"4.1.0"},"reference-count":63,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real\u2010world effectiveness of eptinezumab for migraine prevention in Asian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eptinezumab is a monoclonal antibody that targets calcitonin gene\u2010related peptide (CGRP), a potent vasodilator with an important role in migraine pathophysiology. Although there is robust clinical evidence from pivotal Phase 3 placebo\u2010controlled trials of the efficacy of eptinezumab for migraine prevention, there are limited data on the real\u2010world effectiveness of eptinezumab in Asian patient cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a non\u2010interventional, prospective, multisite cohort study of adults with migraine (International Classification of Headache Disorders, 3rd edition criteria) in Singapore who were prescribed eptinezumab (100\u2009mg at baseline and Month 3, administered intravenously) and were followed until Month 6. The primary endpoint was change from baseline in monthly migraine days (MMDs) at Month 3 and Month 6. Secondary endpoints were \u226530% and \u226550% responder rates, and change from baseline in the Headache Impact Test\u20106 (HIT\u20106), Migraine Disability Assessment (MIDAS), Migraine\u2010Specific Quality of Life (MSQ), patient\u2010identified most bothersome symptom (PI\u2010MBS), acute medication use at Month 3 and Month 6, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Enrolled patients (completed\u2009=\u200929\/30) had on average 3.4 (SD 2.9) previous preventive treatments; 29\/30 of the patients had trialed at least one previous preventive treatment without benefit. Most had previously trialed oral preventives (87%, 26\/30) and anti\u2010CGRP (70%, 21\/30). Relative to baseline, mean MMDs decreased by 4.3\u2009days (95% CI 2.1\u20136.4;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at Month 3 and 4.9\u2009days (95% CI 2.1\u20137.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at Month 6. At Month 3 and Month 6, 14\/30 (47%) and 15\/29 (52%) of the patients were \u226530% responders, and 6\/30 (20%) and 8\/29 (28%) patients were \u226550% responders, respectively. The number of patients with severe life impairment based on the HIT\u20106 score (total score 60\u201378) decreased from 24\/30 (80%) at baseline to 19\/30 (63%) at Month 3 and 19\/29 (66%) at Month 6. The mean MIDAS score decreased by 24.6 points (95% CI 2.82\u201346.38;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028) at Month 6, and the mean MSQ score increased by 12.2 points (95% CI 5.18\u201319.20;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) at Month 3 and 13.6 points (95% CI 4.58\u201322.66;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) at Month 6. Most patients reported improvement in the PI\u2010MBS at Month 3 (73%, 22\/30) and Month 6 (55%, 16\/29). Acute medication use for headache relief decreased by 3.3\u2009days\/month (95% CI 1.0\u20135.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) at Month 3 and 4.7\u2009days\/month (95% CI 1.7\u20137.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) at Month 6. Treatment\u2010emergent adverse events (TEAEs) were reported in 16\/30 (54%) patients, mostly mild\/moderate in severity. No serious TEAEs led to treatment discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Quarterly eptinezumab administration was effective and well\u2010tolerated in Asian patients with chronic migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14737","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T08:19:47Z","timestamp":1716538787000},"page":"810-824","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A real\u2010world prospective observational study of eptinezumab in Asian patients with migraine"],"prefix":"10.1111","volume":"64","author":[{"given":"Yi Jing","family":"Zhao","sequence":"first","affiliation":[{"name":"Mount Elizabeth Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-9290","authenticated-orcid":false,"given":"Jonathan Jia Yuan","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine National University Hospital  Singapore Singapore"},{"name":"YLL School of Medicine National University of Singapore  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit Kumar","family":"Sonu","sequence":"additional","affiliation":[{"name":"Department of Neurology Singapore General Hospital  Singapore Singapore"},{"name":"Department of Neurology National Neuroscience Institute  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Neurology National Neuroscience Institute  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chai Ching","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Neurology National Neuroscience Institute  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keira Joann","family":"Herr","sequence":"additional","affiliation":[{"name":"Lundbeck Singapore Pte. Ltd.  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Bose","sequence":"additional","affiliation":[{"name":"Lundbeck Singapore Pte. Ltd.  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin Idu","family":"Jion","sequence":"additional","affiliation":[{"name":"Department of Neurology National Neuroscience Institute  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00763-1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-019-01755-1"},{"key":"e_1_2_11_6_1","unstructured":"The Institute for Health Metrics and Evaluation.Health research by location\u2014Singapore.http:\/\/www.healthdata.org\/singapore"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-011-0233-z"},{"issue":"19","key":"e_1_2_11_9_1","first-page":"12","article-title":"Migraine is underdiagnosed and undertreated","volume":"258","author":"Miller S","year":"2014","journal-title":"Practitioner"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.07.008"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3702071.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-0130-4"},{"key":"e_1_2_11_14_1","first-page":"3","article-title":"Economic burden of migraine in Singapore","volume":"3","author":"Ong JJY","year":"2020","journal-title":"Cephalalgia Rep"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1995626"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/CON.0000000000000957","article-title":"Preventive migraine treatment","volume":"27","author":"Burch R","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"key":"e_1_2_11_17_1","first-page":"143","volume-title":"Progress in Brain","author":"Chiang C\u2010C","year":"2020"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13583"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.88.16_supplement.P2.155"},{"key":"e_1_2_11_20_1","first-page":"1","article-title":"Characterization of the intrinsic binding features of three anti\u2010CGRP therapeutic antibodies effective in preventing migraine: a comparative pre\u2010clinical case study of ALD403, LY\u20102951742, TEV\u201048125","volume":"56","author":"Karasek C","year":"2016","journal-title":"Headache"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02123-w"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7665"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00185-5"},{"key":"e_1_2_11_27_1","article-title":"A review of eptinezumab use in migraine","volume":"13","author":"Datta A","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_11_28_1","first-page":"1","volume-title":"Summary of Product Characteristics","author":"Singapore HSA","year":"2022"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200009002-00011"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2008.4.4.158"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00305-5"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.019002107.x"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03069.x"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.988"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0230-7"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14295"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412468677"},{"key":"e_1_2_11_43_1","unstructured":"GanE.More than just a bad headache.Today Online.2018."},{"key":"e_1_2_11_44_1","unstructured":"Singapore Department of Statistics.Population trends 2021.https:\/\/www.singstat.gov.sg\/modules\/infographics\/population"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1154420"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01411-1"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal2999"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01418-8"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14655"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201880"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00521-5"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203081"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13497"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01997.x"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15670"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02774-3"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02668-2"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01688-w"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13946"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419858355"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70209-1"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312233"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:40:02Z","timestamp":1767613202000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/head.14737"],"URL":"https:\/\/doi.org\/10.1111\/head.14737","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"2023-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}